A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. (Q53351927)

13 May 2018

title

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. (English)

1 reference

13 May 2018

0 references

0 references

1 reference

1 reference

1 reference

Richard R Furman

1

1 reference

13 May 2018

Andres Forero-Torres

series ordinal

2

1 reference

13 May 2018

Andrei Shustov

series ordinal

3

1 reference

13 May 2018

Jonathan G Drachman

series ordinal

4

1 reference

13 May 2018

publication date

1 February 2010

1 reference

13 May 2018

published in

Leukemia & Lymphoma

1 reference

13 May 2018

volume

51

1 reference

13 May 2018

page(s)

228-235

1 reference

13 May 2018

issue

2

1 reference

13 May 2018

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Prospects for CD40-directed experimental therapy of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

CD40 activation: potential for specific immunotherapy in B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903440946

10.3109/10428190903440946

21 January 2018

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

20038235

1 reference

13 May 2018